Huons Global has finalized and announced a shareholder return policy to protect the rights and interests of minority shareholders during the process of promoting a merger between its subsidiaries.


On June 8, Huons Global Inc. held a board meeting and resolved to distribute a portion of the new merger shares that it will acquire from the merger of its subsidiaries, Huons and Huons Lab, in the form of an in-kind dividend only to general shareholders, excluding the largest shareholder, related parties, and treasury shares.


The finalized shareholder return plan was pursued to maximize the rights and interests of general shareholders affected by the subsidiary merger, as announced at the shareholder meeting held on June 4.

Huons Global to Distribute New Shares as Stock Dividend Upon Subsidiary Merger View original image

Subsequently, the Huons Global Special Committee, which includes external experts, discussed measures to prevent the dilution of shareholder value for Huons Global, the parent company, as a result of the merger. As a result, the committee recommended that a portion of the new merger shares in Huons that Huons Global will receive be distributed as an in-kind dividend to general shareholders. The board of directors accepted this recommendation and confirmed the return policy through a resolution.


The key point of this return policy is its ‘focus on general shareholder benefits.’ As the holding company, Huons Global will directly distribute a portion of the new Huons shares it is allocated through the subsidiary merger to general shareholders only, in the form of an in-kind dividend. This dividend will not be allocated to the largest shareholder, related parties, or treasury shares held by the company. This structure ensures that general shareholders can most directly and clearly enjoy the fruits of growth resulting from the subsidiary merger.


Huons Global’s shareholding structure consists of 57.14% held by the largest shareholder and related parties, 3.57% in treasury shares, and 39.28% held by general shareholders. Huons Global plans to convert the total number of new Huons shares it will receive from the merger based on the general shareholders’ ownership ratio, and 26,038 shares, which constitute 30% of this amount, will be distributed as an in-kind dividend. General shareholders of Huons Global will receive one share for every 20 shares held.


When converted based on the Huons merger price of 34,062 won per share, the dividend amounts to approximately 1,780 won per share. If combined with the previously announced mid- to long-term cash dividend policy of 800 won per share (200 won per quarter), the annual dividend per share increases to 2,580 won. The total annual dividend payout is approximately 3.15 billion won, and the dividend yield is 9% based on the closing price on June 5.


This in-kind dividend will be paid if the merger is finalized following a series of extraordinary general meetings scheduled to be held sequentially starting next month. The dividend is planned to be paid in April next year after approval at the regular general meeting of shareholders in March, coinciding with the end of the lock-up period.


Prior to this, on July 3, an extraordinary general meeting of Huons Global will be held to ask shareholders whether the holding company should exercise its voting rights regarding the merger between subsidiaries. The company stated that any restrictions on the voting rights of the largest shareholder and related parties will follow guidelines to be announced in accordance with government policy direction.


Huons Global plans to exercise its voting rights at the extraordinary general meetings of Huons and Huons Lab, the merging subsidiaries, in accordance with the will of its shareholders.


If the merger is completed, Huons will add innovative bio-platform technologies, such as the human-derived hyaluronidase held by Huons Lab, to its synthetic drug pipeline. In addition, through increased R&D investment, the company expects to secure a favorable position for certification as an innovative pharmaceutical company under the government’s ‘National Health Insurance Drug Price System Improvement Plan.’ If designated as an innovative pharmaceutical company, benefits include receiving up to 60% of the original drug price for new generics for four years. For already-listed generics, a drug price of up to 49%—higher than the basic rate of 45%—can be recognized for up to four years. The Huons Lab pipeline currently under development is also expected to benefit from stable, large-scale R&D funding necessary for global technology transfer by being integrated into Huons, resulting in a win-win effect.



Suyeong Song, CEO of Huons Global, stated, “The decision to allocate 30% of the new merger shares as an in-kind dividend is meaningful as it reflects sincere communication with general shareholders and an independent, thorough review by the special committee,” and added, “We will conclude the merger process by respecting the will of our shareholders at the upcoming extraordinary general meeting, and ultimately achieve results that maximize corporate strength and shareholder value.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing